share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

SEC announcement ·  Mar 20 04:41
Summary by Futu AI
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 20,054 Class A shares on 03/19/2024, as per the latest filing. These shares, initially acquired on 09/01/2016 as founders shares, were part of Borgeson's compensation from the issuer. The sale is expected to yield an aggregate market value of approximately $216,423. Borgeson's transaction history over the past three months includes the sale of 111,717 shares, generating total gross proceeds of around $1,293,849. The upcoming sale follows a series of transactions by Borgeson, with the most recent sale occurring on 03/05/2024.
Recursion Pharmaceuticals, Inc. Director Blake Borgeson is set to sell 20,054 Class A shares on 03/19/2024, as per the latest filing. These shares, initially acquired on 09/01/2016 as founders shares, were part of Borgeson's compensation from the issuer. The sale is expected to yield an aggregate market value of approximately $216,423. Borgeson's transaction history over the past three months includes the sale of 111,717 shares, generating total gross proceeds of around $1,293,849. The upcoming sale follows a series of transactions by Borgeson, with the most recent sale occurring on 03/05/2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.